MRI developer Fonar has announced that it has resolved its pending patent infringement litigation with Elscint. Terms of the agreement were not released.The deal adds another to the list of companies that have settled MRI patent disputes with Fonar.
MRI developer Fonar has announced that it has resolved its pending patent infringement litigation with Elscint. Terms of the agreement were not released.
The deal adds another to the list of companies that have settled MRI patent disputes with Fonar. Hitachi, Philips, Siemens, Toshiba, and Shimadzu have all reached settlements with them in recent years, while GE lost its legal battle with the firm in 1997, paying a total of $128.7 million (SCAN 7/9/97).
In other Fonar news, the Melville, NY-based company has appointed Sol Ginzburg as vice president of sales. He had recently served as director of international sales for the firm.
Fonar also announced that Pennsylvania Medical Group has acquired another of its Quad 12000 devices for an imaging center in Reading, PA. The group already employs a Quad 12000 scanner at an imaging facility in Philadelphia. Fonar valued the groups latest purchase at $1.2 million.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.